Our mission is to detect cancer early,
when it can be cured.
GRAIL (Nasdaq: GRAL) is focused on alleviating the global burdenof cancer by using the power of next-generation sequencing,
population-scale clinical studies, and state-of-the-art machinelearning, software, and automation to detect and identify multiple
deadly cancer types in earlier stages.

The GRAIL Journey From Idea to Innovation and Impact
2016

2018

2021

2022

2023

GRAIL establishedbased on NIPT
research discovery
in 2015• Surpassed 100k
enrolled in clinicalprogram• Commerciallaunch of Galleri®

• Surpassed 200k
enrolled in clinicalprogram• Published• >215k commercial
seminalGalleri® tests
PATHFINDER andcompleted1
SYMPLIFY study• >11k prescribers
results in The
Lancet and The
Lancet Oncology,
respectively• BreakthroughDevicedesignation
granted by FDA• First pharma
partnershipannounced

2024

Grail At a Glance>65,000 square feetof CAP-accredited, CLIA-certified
lab facilities with capacity for
5M+ tests per year
Office Locations
Menlo Park, CA

Washington, D.C.

Research Triangle Park, NC

London, UKHeadquarters

Awards2023 Change theWorld List

Intelligent Diagnostics
Silver Winner, 2023

Best Inventionsof 2022 List

Fortune

The Edison Awards

Time Magazine

Breakthroughs of theYear List, 2022

2022 World Changing
Ideas Awards

The Atlantic

Fast Company

The Galleri® Test
Revolutionizing what’s possible in cancer screening with a first-of-its-kind,Multi-Cancer Early Detection (MCED) test2

1

screening test

50+

99.5%

cancer types
detected

specificity

69%

Stage II sensitivity for 12 deadly
cancers representing 2/3 of cancer
mortality in the U.S.

88%

localization
accuracy

Backed by Rigorous Clinical Evidence>200
scientificand medicalpublications>450K

tests ran across clinicaland commercial
applications>385K

participants across
9 clinical studies

When added to recommended screenings,
Galleri® doubled the number of cancers detected
in a clinical study, and 48% of subsequently
confirmed cancers were in stages I-II3,4

Significant Commercial Opportunity
Addressable market of 300 million individuals in major markets
over the age of 50, including more than 100 million in the U.S.
Exclusive licenses to more than 530 granted patents globallyOwn or co-own more than 130 issued patents, with more than
850 pending patent applications

Sustaining apatient-first
corporate
culture thatchampionsdiversity

2023 Best
Place toWork Lists
Built In & Comparably

Media Contacts
Trish Rowland
trowland@grailbio.com

Our diverse employee pool includes expertise fromindividuals with a variety of backgrounds and specialties,
enriching our collective knowledge and skill-base.
We are committed to actively promoting and fostering
a community of belonging and inclusivity where all
employees feel inspired and empowered to innovate,collaborate, and deliver on our mission.

Learn More at grail.com
Kristen Davis
kdavis@grailbio.com

Foward-Looking Statements
This communication contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as“aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,”“would,” or “will,” the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks,
uncertainties, and assumptions about us, may include expectations and projections of our future performance, potential market opportunity,performance of our Galleri test and anticipated trends in our business.
These statements are only predictions based on our current expectations and projections about future events and trends. There are importantfactors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressedor implied by the forward-looking statements, including those factors discussed under the section entitled “Risk Factors” in our Quarterly Reporton Form 10-Q filed by GRAIL (the “10-Q”), as may be further amended. Moreover, we operate in a dynamic and rapidly changing environment.
New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on ourbusiness or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements todiffer materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances thatare difficult to predict and many of which are outside of our control, including performance of Galleri in a real world setting and across differing
populations, our ability to obtain regulatory approval, the strength of our intellectual property portfolio, our ability to complete ongoing or potential
future clinical trials, our ability to obtain approval or clearance by the U.S. Food and Drug Administration and our estimate of the size of and ourability of our addressable market. Although we believe the expectations and projections expressed or implied by the forward-looking statements
are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results and financial condition
may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation toupdate any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised
expectations or to reflect new information or the occurrence of unanticipated events.
This communication shall not constitute an offer of any securities for sale, nor shall there be any offer, sale or distribution of securities in any
jurisdiction in which such offer, sale or distribution would be unlawful prior to appropriate registration or qualification under the securities laws ofsuch jurisdiction.
For additional information with respect to GRAIL, please refer to our annual reports, quarterly reports and other documents that we file with theSecurities and Exchange Commission from time to time.

About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify
DNA shed by cancer cells, which can act as a unique “fingerprint” of cancer, to help screen for some of the deadliest cancers that don’t haverecommended screening today, such as pancreatic, esophageal, ovarian, liver, and others.* The Galleri test can be used to screen for cancer
before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of
the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare
provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA)
test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
For more information about Galleri, visit galleri.com.
* Sensitivity in study participants with – Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV). Esophagus
cancer 85.0% overall (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV). Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II,
87.1% stage III, 94.7% stage IV). Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV).
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect
all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect
cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer
Signal Not Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medicallyestablished procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due
to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative(a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test InformationThe GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the Collegeof American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has
not been cleared or approved by the U.S. Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform highcomplexity testing. The Galleri test is intended for clinical purposes.

FOOTNOTES
1 All statistics are as of June 30, 2024
2 Data drawn from CCGA and PATHFINDER clinical trials. The Galleri® test should be used in addition to recommended cancer screenings.
3 PATHFINDER - Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection. (PATHFINDER): a prospective cohort
study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2.
4 CCGA - Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using anindependent validation set. Ann Oncol. 2021;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806.